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Abstract
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Many of today’s drug discovery programs utilize high-throughput screening methods that rely on
quick evaluations of protein activity to rank potential chemical leads. By monitoring biologically
relevant protein-ligand interactions, NMR can provide a means to validate these discovery leads and
to optimize the drug discovery process. NMR-based screens typically use a change in chemical shift
or linewidth to detect a protein-ligand interaction. However, the relatively low throughput of current
NMR screens and their high demand on sample requirements generally makes it impractical to collect
complete binding curves to measure the affinity for each compound in a large and diverse chemical
library. As a result, NMR ligand screens are typically limited to identifying candidates that bind to
a protein and do not give any estimate of the binding affinity. To address this issue, a methodology
has been developed to rank binding affinities for ligands based on NMR-based screens that use
1D 1H NMR line-broadening experiments. This method was demonstrated by using it to estimate
the dissociation equilibrium constants for twelve ligands with the protein human serum albumin
(HSA). The results were found to give good agreement with previous affinities that have been
reported for these same ligands with HSA.

INTRODUCTION
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Over the last decade, nuclear magnetic resonance (NMR) spectroscopy has evolved as an
important tool for drug discovery.1 Current NMR screening methods complement structural
biology efforts by validating chemical leads from high-throughput screening (HTS) prior to
initiating a structure-based drug design program.2–7 The first NMR screening methods, such
as SAR by NMR,4 RAMPED-UP NMR,8 and NMR-SOLVE,9 were developed to identify
ligands that bind a therapeutic target in a biologically-relevant manner by observing chemical
shift changes in two-dimensional (2D) 1H-15N HSQC spectra. However, these methods tend
to be resource-intensive. Also, their relatively low throughput makes it impractical to use these
methods for collecting complete binding curves that allow binding affinities (often represented
by the dissociation equilibrium constant, KD) to be measured as an integral component of an
NMR screen. To overcome these issues, recent methods such as MS/NMR10 and multi-step
NMR screen11 have applied a tiered approach to screening that joins complementary
techniques to increase throughput and minimize resource usage. For instance, the multi-step
NMR screen combines one-dimensional (1D) 1H NMR line-broadening experiments and
2D 1H-15N HSQC chemical shift perturbation experiments to identify drug discovery leads
from a biologically-relevant, small-molecule library.12
Ligand-focused 1D NMR methods are well suited to identify hits from large chemical libraries
because they favor weak-affinity ligands (i.e., ligands with KD values in the range of μM-mM),
decrease data-collection time, and reduce overall sample requirements.7 In addition, with the
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advent of sample changers and flow-probes, ligand-focused 1D NMR experiments can be
readily adapted to automation to give a corresponding increase in throughput.7, 13–17 A
number of fast, ligand-focused 1D NMR experiments exist that exploit differences in relaxation
rates, diffusion rates, saturation transfers, or NOE transfers to identify protein-ligand
complexes.3, 18 In general, a binding event is identified by using a change in linewidth or
chemical shift in the free ligand 1D-1H NMR spectrum upon the addition of a protein. However,
using these measurements to determine the dissociation equilibrium constant for a proteinligand complex as part of an NMR screen is still a challenging task.19–25
Similar to traditional measurements,20 NMR methods rely on the collection of multiple data
points to accurately determine a dissociation equilibrium constant or binding affinity for a
protein-ligand interaction.9 This approach is usually impractical in a high–throughput mode
that requires a rapid method for characterizing and ranking binding affinities. Examples of
single-point KD measurements using 1D NMR experiments have recently been described that
use 19F-containing compounds21, 22 or the displacement of known low-affinity inhibitors.
24, 26 Unfortunately, these approaches are typically limited in practice because known lowaffinity inhibitors or a large library of “drug-like” and structurally diverse 19F-containing
compounds are not available for a wide range of protein targets.
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This report discusses a new NMR screening method that can be used to determine the relative
ranking of binding affinities using a variation of traditional 1D 1H NMR line-broadening
experiments.27, 28 This approach correlates the ratio of NMR peak height for free and bound
ligands to the fraction of bound ligand in a protein-ligand complex. This method is illustrated
by using human serum albumin (HSA) as a model protein, which is an important secondary
target for efficacy screening and a well-established system for monitoring protein-ligand
interactions.29

THEORY
Binding interactions between a large protein (MW > 5000 Da) and a low molecular weight
ligand (MW < 500 Da) can be examined by using the decrease in NMR peak height that occurs
upon the addition of a protein to a solution with constant ligand concentration. NMR linebroadening experiments follow an opposite protocol from typical experiments that measure
KD values, where ligands are added to solutions that contain a constant protein concentration.
Thus, a different form for the standard Langmuir binding isotherm is required in the former
type of study. If it is assumed that a protein (P) has a 1:1 binding with a ligand (L), the
dissociation equilibrium constant for this interaction can be represented by the following
equation

NIH-PA Author Manuscript

(1)

where [P]F is the concentration of the free protein at equilibrium, [L]F is the corresponding
concentration of the free ligand, and [PL] is the concentration of the resulting protein-ligand
complex.
Rearrangement of eq 1 produces the following binding isotherm, in which fB represents the
“fractional occupancy”, or the fraction of bound ligand.
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(2)

It is assumed in many types of binding studies that the total ligand concentration [L]T is
approximately equal to the free ligand concentration; however, this assumption is not
applicable to the NMR line-broadening experiments used in this study because [L]T is not
necessarily in excess of the maximum complex concentration [PL]. Also, a direct measurement
of the free protein concentration is not possible for the method described in this report.
Therefore, eq 3 was derived to describe this situation in terms of the total protein concentration
[P]T and total ligand concentration [L]T that are known to be present in the system (see
Appendix for derivation).

(3)
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Eq 3 can be simplified to approximate the fractional occupancy in terms of the total ligand
concentration [L]T and total protein concentration [P]T by using a Taylor series expansion and
the assumption that [L]T > [P]T.
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(5)

(4)

The fractional occupancy for a protein-ligand complex can be measured using a ratio of NMR
peak height (1−IB/IF), where IB is the sum of ligand NMR peak heights in the presence of the
protein and IF is the sum of NMR peak heights for the free ligand. Therefore, B (the NMR peak
height ratio) represents an easily measurable response of ligand binding that can be described
in terms of the fraction of bound ligand (fB) and the NMR-linewidth for the free (νF) and bound
(νB) states (see Appendix for derivation).

Combining eq 4 and eq 5 leads to a new binding isotherm for this system, as shown below,

(6)

The unit-less NMR-linewidth ratio constant (c), as defined in eq 6, accounts for the proportional
change in ligand linewidth upon binding of a ligand to a protein. Once a ligand is bound, the
free ligand linewidth (νF) of a ligand resonance adopts the linewidth of the protein (νB) and
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the increase in linewidth produces a corresponding decrease in peak height measured by the
ratio of NMR peak height (B).
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The dissociation equilibrium constant for a protein-ligand complex that is calculated using eq
6 is based on relative changes in NMR peak height by fitting the given binding isotherm to a
complete protein titration curve. This is impractical in the context of an NMR high-throughput
screen where only a single titration point is measured. However, eq 6 can be rearranged to
solve for KD to yield an estimate for KD that is based on [P]T, [L]T, c and Bsingle, where
Bsingle is the fractional occupancy at a single protein concentration. The resulting expression
is shown in eq 7.

(7)

For proteins such as HSA that possess multiple non-specific binding sites, the decrease in
ligand signal at a relatively high protein concentration will be an average of specific and nonspecific binding. To correct for this effect, the non-specific binding term n[P]T that corresponds
to a linear increase in fraction bound with the addition of protein is simply added to eq 6, as
shown in eq 8.
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(8)

EXPERIMENTAL SECTION
Materials
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The HSA (essentially fatty acid free, ≥ 96% pure), choline bromide (~ 99% pure), clofibrate,
furosemide, phenol red, phenylbutazone, phenytoin (~ 99% pure), sodium salicylate,
tolbutamide, uridine 5′-monophosphate (98–100% pure) and warfarin (> 98% pure) were
purchased from Sigma (St. Louis, MO). The bromophenol blue (ACS reagent grade, 95% pure),
bromocresol green (ACS reagent grade, 95% pure), and ibuprofen were from Sigma-Aldrich
(Milwaukee, WI). The dimethyl sulfoxide-d6 (99.9% D), deuterium oxide (99.9 atom% D) and
naproxen (98% pure) were obtained from Aldrich (Milwaukee, WI). The 3-(trimethylsilyl)
propionic-2,2,3,3-d4 acid sodium salt (98% D) was purchased from Cambridge Isotope
(Andover, MA). The potassium phosphate dibasic salt (anhydrous, 99.1% pure) and monobasic
salt (crystal, 99.8% pure) were purchased from Mallinckrodt (Phillipsburg, NJ).
Apparatus
All NMR spectra were collected on a Bruker 500 MHz Avance spectrometer (Billerica, MA)
equipped with a triple-resonance, Z-axis gradient cryoprobe and using a Bruker BACS-120
sample changer and IconNMR software for automated data collection. Spectra were collected
at 298 K using 512 transients, a sweep-width of 6009 Hz, 16 K data points and a relaxation
delay of 2.0 s. The residual HDO resonance signal was suppressed with pre-saturation. The
total experiment time, including sample changing for each spectrum, was approximately 33
min.
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All small-molecule ligands that were used in this study were selected based on their previously
reported KD values for HSA and their good solubility in an aqueous solution.29 The smallmolecule ligand samples were individually prepared in 10 mL stock solutions that contained
20 μM ligand, 1% (v/v) dimethyl sulfoxide-d6 (DMSO-d6), 10 μM 3-(trimethylsilyl)
propionic-2,2,3,3-d4 acid sodium salt (TSP) and pH 7.0 (uncorrected) 50 mM potassium
phosphate buffer prepared in deuterium oxide.
A series of ten HSA stock solutions were prepared in deuterium oxide by making serial dilutions
from a 200 μM master solution of HSA in deuterium oxide. The final concentrations of HSA
in these stock solutions ranged from 0 μM to 200 μM and were prepared so that a 10 μL addition
of the HSA stock solution to 490 μL of a free ligand solution resulted in final concentrations
of 0 μM, 0.1 μM, 0.2 μM, 0.4 μM, 0.6 μM, 0.8 μM, 1 μM, 2 μM, 3 μM, and 4 μM HSA,
respectively. These mixtures were prepared individually for each ligand in 1.5 mL
microcentrifuge tubes and then transferred to NMR tubes. The sample for each titration that
contained 0 μM HSA was used as the reference for calculating the free ligand intensities (IF)
and free ligand linewidths (νF). All binding studies performed with these solutions were
conducted at 25°C.
1D 1H NMR Binding Curves
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Spectra were processed with the ACD/1D NMR manager (Advanced Chemistry Development,
Inc., Toronto, Ontario). A linear prediction algorithm was applied to the FID in the forward
direction and the resulting FID was Fourier transformed. The NMR spectrum was phaseadjusted and baseline-corrected. The residual water signal was removed for clarity using the
solvent removal function in ACD. This function simply sets the spectrum’s baseline to zero
around the residual water signal. All ligand resonance peaks were visually selected and peak
positions were measured relative to a TSP reference set to 0.0 ppm. Peak height were measured
relative to the DMSO-d6 peak at 2.69 ppm that was normalized to an height of 1.00. The DMSOd6 peak was completely recovered during the 1D 1H NMR experiment using a 2.0 s recycle
delay, which is >3x the T1 for DMSO in D2O at 299K (0.3–0.5 s).30, 31 Individual peak
heights in the aromatic region for each ligand were summed to obtain the free (IF) and bound
(IB) heights at each titration point. The peak-height ratios were plotted versus total protein
concentration and fit to eq 8 using the program KaleidaGraph version 3.52 for Windows
(Synergy Software., Reading, PA) to estimate the KD value for each protein-ligand complex.
The average NMR-linewidth ratio (c) for each ligand was estimated by using eq 6, where νB
was taken to be approximately 94.2 Hz using a previously measured correlation time for HSA
of 41 ns.32 The value for νF was calculated as described in the next section. The fit of each
binding curve was constrained so that KD ≥ 0 in these studies.
Measuring a Free Ligand NMR-linewidth (νF)
To measure the free ligand linewidth (νF) for use in eq 6, the NMR spectrum for each free
ligand (i.e., as obtained in a solution containing no HSA) was processed as described above to
avoid any distortion in linewidth resulting from processing. NMR peak linewidths were
measured using the ACD/1D NMR manager peak fitting routine. The average peak linewidth
was used to report νF for each ligand and to calculate the NMR-linewidth ratio.
Simulated High-Throughput Screening by NMR
To simulate the outcome of an NMR high-throughput screening assay, a single protein
concentration [P]T from the full titration curve was used. On average, the 0.2 μM HSA titration
point yielded a large response for all 12 ligands without reaching saturation. The static total
ligand concentration [L]T was 20 μM. A simulated response curve was generated by fitting a
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range of KD values to a range of ideal Bsingle values calculated using eq 7. The measured
Bsingle value for each ligand at the 0.2 μM HSA titration point was used to calculate a singlepoint binding constant from eq 7 and compared to the simulated response curve. This simulated
experiment used both the individual c values calculated for each ligand from the full titration
experiment and an average c value calculated from the 12 NMR titration curves. The singlepoint dissociation equilibrium constant for each ligand was calculated using this average c
value.

RESULTS AND DISCUSSION
Measuring KD from 1D 1H NMR Line-Broadening Experiments
The development of NMR-based screening assays that monitor changes in chemical shifts or
linewidth as a means to identify or verify initial chemical leads has evolved to become an
increasingly important component of drug discovery efforts in the biotechnology and
pharmaceutical industry.33, 34 Nevertheless, the direct measurement of a binding affinity from
a high-throughput NMR screen is generally lacking.21–25 A decrease in the height of a ligand’s
NMR signal in the presence of a protein is commonly used in NMR-based screens to monitor
the formation of a protein-ligand complex. 1D 1H NMR spectra of small-molecules (MW ≤
500 Da) usually have extremely sharp peaks due to slow dipole-dipole relaxation (T ).3
2
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Binding to a high molecular weight agent like a protein induces peak broadening and a
corresponding decrease in the ligand’s NMR signal height because the bound ligand now
experiences the shorter relaxation time of the protein. This effect is illustrated in Figure 1 using
binding by the protein HSA to the drugs phenytoin and naproxen as examples.
The observed increase in ligand linewidth in such an experiment will depend on a number of
factors that include the dissociation equilibrium constant for the protein-ligand interaction,
KD. In general, the observed change in the ligand’s linewidth (νobs) for the fast exchange limit
will follow the result shown below.

(9)

NIH-PA Author Manuscript

In eq 9, fB is the fraction of the bound protein-ligand complex, νF is the free ligand NMRlinewidth, and νB is the linewidth for the bound state of the ligand (see the Appendix for an
explanation regarding the above expression for fB). Eq 9 shows that an increase in the observed
ligand linewidth will be related to the free and bound ligand linewidths and the value of KD
for the protein-ligand complex. If it is assumed that the linewidth of the protein-ligand complex
is significantly larger than that for the free ligand, the ratio of the ligand linewidth in the
presence and absence of the protein should represent the remaining free ligand concentration,
as indicated by eq 6.
This relationship assumes that there is a lack of any significant contribution of chemical or
dynamic exchange to the observed change in linewidth. This is a reasonable assumption in the
context of a high-throughput NMR screen against a single protein target. First, initial chemical
leads tend to be weak binders in the fast exchange regime, where the linewidth change of the
ligand will be dominated by the linewidth of the protein. Second, biologically relevant binders
will interact with the same or similar binding sites on the protein. Under these circumstances,
the ligand may experience a relatively constant contribution of chemical and dynamical linebroadening. Thus, the minimal contribution of linewidth from exchange processes should not
affect the relative ranking of the ligand binding affinities that are obtained when using such an
experimental approach.
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The validity of this method for high-throughput screening by NMR was examined by using
twelve ligands with previously determined binding affinities to HSA.29, 35–38 These ligands
were used to examine the relationship between the estimated values for KD and the relative
ratios of the NMR Peak height. Samples containing 20 μM of any given ligand were titrated
with solutions that contained 0 to 4 μM of HSA to develop full binding curves for each of the
twelve ligands. As a control, two suspected non-binding ligands (i.e., choline bromide and
uridine-5′-monophosphate) were also screened in the presence of HSA with no observable
decrease in signal (data not shown). The KD values that were obtained by this method (see
Table 1) were experimentally determined by directly fitting the resulting binding curve of each
ligand to eq 8. These fits gave a sum of residuals squared that ranged between 0.977 and 0.998
over the ten concentrations of HSA that were tested. Figure 2 shows the results that were
obtained for three of the tested ligands, which have previously reported dissociation
equilibrium constants that ranged from 0.7 to 36.8 μM. These figures and the corresponding
fits illustrate the ability of this approach to be used with ligands that have weak-to-moderate
strength binding to proteins such as HSA.
Co-variance of KD and the NMR-linewidth Ratio (c)
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Ideally, the dissociation equilibrium constant (KD) and the NMR-linewidth ratio (c) could be
simultaneously derived by fitting eq 6 to the experimental NMR binding curves. Unfortunately,
KD and c are completely covariant. This requires an approximation for c in order to calculate
KD from the NMR binding curves. The linewidth of a protein (νP) may provide a lower estimate
of νB if it is assumed that νB is dominated by the protein linewidth (νP). Estimations of νP can
be made from the correlation time (τc) of the protein by using the intramolecular dipole-dipole
relaxation rate constant (T2−1). 39

(10)

where

(11)
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In these equations, J(ω) is the normalized spectral density function, μo is the vacuum
permeability, γ is the magnetogyric ratio, ω is frequency (rad s−1), ħ is Plank’s Constant, B0
is the static magnetic field strength and r is the hydrodynamic radius of the protein. In addition,
the Stokes-Einstein equation can be used to relate τc to the molecular weight (MW) for a
globular protein,40

(12)

where T is the temperature, k is the Boltzmann constant, η is the viscosity of the solvent, r is
the radius and ρ is the shape constant.
The reliability of eq 12 to approximate a protein correlation time from its molecular weight is
illustrated from a comparison between 27 experimental τc values 41, 42 and correlation times
predicted using eq 12 (figure 3A). A linear best-fit was obtained with an R2 of 0.81 in this case.
J Comb Chem. Author manuscript; available in PMC 2009 November 1.
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For a high-throughput screen, νp can be estimated from the molecular weight of a protein by
using this approximation for τc with a shape constant of 1.32 combined with eq 10 and 11. The
shape constant was determined by optimizing a linear fit between the experimental and
predicted τc values shown in Figure 3A by varying ρ. The result is an approximate correlation
between νP and MWP, as shown in eq 13.
(13)

This dependency of linewidth on the size and shape of a protein is plotted in Figure 3B. For
HSA (MW, 66 kDa), the correlation time (41 ns) has previously been measured using timeresolved fluorescence.32 This correlation time was used to calculate the value used for νP,
which was 94.2 Hz.
The free ligand linewidth (νF) can be measured directly from the NMR spectra of the free ligand
using an average ligand linewidth. Average νF values measured from the free ligand NMR
spectra are reported in Table 1. However, for large and diverse chemical libraries it may not
be feasible to measure an accurate linewidth for each compound. Alternatively, νF is generally
between 1 and 2 Hz for many small-molecules (MW, 500 < Da), which provides a reasonable
estimate for νF to calculate an average value for c.
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Sensitivity of KD and NMR-linewidth Ratio (c)
A closer examination of eq 6 indicates that the NMR-linewidth ratio (c) acts as a scaling factor
in the calculation of KD, with a larger c value resulting in a proportionally larger KD value.
Unfortunately, small variations or errors in the measurement of νF will result in proportionally
larger variations in both c and KD. In the context of high-throughput screening by NMR, an
incorrect estimate of c will result in a systematic underestimation or overestimation of KD.
However, the relative ranking of the ligand binding affinities will be maintained. In addition,
a lower limit to c is inherently defined by eq 6.
Comparison of Estimated KD Values with Literature Values
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Table 1 shows the dissociation equilibrium constants that were measured for twelve ligands
known to bind HSA by using the 1D 1H NMR line-broadening method that is described in this
report. Previously reported KD values from the literature are also listed for these twelve ligands.
35–37, 43–67 In general, there is good agreement between the K values that were estimated
D
by NMR and those values reported in the literature. Variations in temperature, pH or buffer
conditions may partly explain the range of KD values observed in the literature. There may
have also been differences in the fatty acid content of the HSA preparations, which can affect
the reported KD values. Thus, 1D 1H NMR line-broadening measurements appear to provide
reliable preliminary estimates for binding affinities as part of a high-throughput screening
assay.
One limitation of the model that was used for this analysis is the assumption of only a single
site interaction between the ligand and protein. There are many cases for which multisite
binding or other effects (e.g., allosteric interactions) are present that give rise to more complex
binding models.3, 29,35,39 Multisite binding also contributes to the relatively large range of
KD values reported in the literature for HSA ligands. In these situations, the KD values listed
in Table 1 (for both the NMR and literature results) should be regarded as weighted averages
and as measures of the global affinity for a particular ligand with HSA. This averaging effect
may be more pronounced for the NMR method than for other techniques because of the
practical limit in ligand concentration that could be used to provide a measurable signal. There
is also a practical limit to the number of concentrations and data points that could be sampled
J Comb Chem. Author manuscript; available in PMC 2009 November 1.
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to give a binding curve. This effect may explain why the NMR-derived KD values tend to be
lower than the literature values, because the use of higher concentrations for the NMR studies
would give a higher weight and likelihood to the detection of weaker interactions between the
ligand and protein.
A number of other practical limitations also need to be considered in the use of NMR for these
binding studies. For instance, the NMR resonances that are specifically involved with protein
binding have been shown to exhibit the most dramatic changes in linewidth.27, 28 Therefore,
there are inherent errors caused by summing all peak height and selectively excluding ligand
peaks due to an overlap with buffer and protein resonances. In addition, errors in the
measurement of peak height might arise at lower ligand concentrations due to the difficulty of
accurately identifying and selecting peaks under these conditions. The result could be either a
low or high estimate for KD, depending on the disparity in linewidth changes and on which
peaks are excluded. Using overlapping peaks would introduce an alternative error because the
observed height is the sum of multiple peaks that cannot be easily de-convoluted. Also, the
analysis of hundreds to thousands of NMR spectra in a high-throughput screening assay
precludes a manual inspection to selectively determine which peaks to include or exclude.
Estimating KD based on Single-point 1D 1H NMR Line-Broadening Measurements
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Since NMR-based screens are a common component of the drug discovery process in the
pharmaceutical industry, single-point estimates of ligand binding affinities could be an
extremely valuable tool to initially rank and prioritize chemical leads. During the iterative drug
optimization process, it is typical to focus on a small set (i.e., 3–5 compounds) of structurally
distinct chemical classes that are amenable to synthetic modification and that exhibit drug-like
characteristics.68 For this work, an NMR screen could be used to verify the presence of a
specific and biologically-relevant interaction involving a protein target and to rank the relative
binding affinity of the screened ligands to simplify the selection of promising lead compounds.
This approach was illustrated in this study by simulating NMR high-throughput screening
results for the twelve compounds that were used in the previous binding study.

NIH-PA Author Manuscript

First, using an average c value of 45.7 ±11.6 and an HSA concentration of 0.2 μM, single point
KD values were calculated for a range of Bsingle values using eq 7. The result of this calculation
are shown in Figure 4. Superimposed on the single point curve in Figure 4A are the KD values
reported in Table 1 plotted versus the experimental B values at 0.2 μM HSA. Superimposed
on the single point curve in Figure 4B are the KD values from Table 1, where the corresponding
c values were used to determine a best-fit to eq 8. This represents the typical protocol that
would be used in a high-throughput screen and shows that an average value of c is acceptable
for use when individual estimates of c may not be practical. A comparison of Figure 4B with
the theoretical curve based on eq 7 indicates that the single-point method can provide a
reasonable approximation for KD.
For the twelve compounds that were considered in Figure 4B, all compounds gave single-point
estimates that agreed within a range of one standard deviation over the range of binding
affinities and concentrations that were tested. All twelve compounds had experimental and
single-point estimates for KD that agreed within two standard deviations. A higher deviation
was observed in Figure 4A for ligands with higher KD values. This occurs because of
differences between the individual c values and the average c values. Also, eq 8 is more
sensitive to small changes in c at these high KD values. This occurs because, at high KD values,
vanishingly small differences in NMR intensities correspond to large differences in KD. In
other words, this method is reaching a practical limit of detection since KD rapidly approaches
infinity as NMR peak height changes approach zero.
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The relative ranking of the KD values were also the same for results that were obtained by the
single-point calculations or the full titration method. These results indicate that the single-point
method can, at least in cases such as these, provide a preliminary estimate of KD values and
binding affinities that can be used in the context of a high-throughput screening assay. At a
minimum, the relative changes in linewidth provide a rapid and efficient mechanism to
prioritize NMR screening leads for further evaluation. However, it is still recommended that
a more robust approach for measuring binding affinities for promising leads follow the NMR
ligand affinity screen. This precaution follows, in part, from the fact that the accuracy of the
KD values that are measured from the single-point 1H NMR line-broadening experiments will
be strongly dependent on having a reasonable estimate for the value of NMR-linewidth ratio
(c) in such a study.

CONCLUSIONS
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High-throughput NMR screening methods are commonly used to determine protein-ligand
binding interactions. A methodology to estimate binding affinities and rank chemical leads
from 1D 1H NMR line-broadening experiments was described in this report. A new equation
was derived that allowed a dissociation equilibrium constant for protein-ligand binding to be
determined from a single-point NMR peak height change. This approach assumes a single
binding-site interaction that is in the NMR fast-exchange regime with uniform changes in
compound linewidths. These are reasonable assumptions during the initial stages of a drug
discovery effort, where typical lead compounds will have weak μM-mM dissociation constants.
The technique was demonstrated by measuring dissociation equilibrium constants for twelve
compounds that bind to HSA. Although this approach does have a number of practical
limitations that must be considered, a reasonable correlation was observed between the binding
affinities that were estimated by NMR and previously reported literature values for the tested
compounds. Such information should be quite useful if the intent is to use the 1D 1H NMR
line-broadening method as part of high-throughput screening to rank the binding affinities for
ligands to a given protein. For instance, this approach could be used to prioritize chemical leads
during a drug discovery process before these leads undergo further evaluation by secondary
assays that can provide a more robust measurement of dissociation equilibrium constants. This
technique is also a general approach that can be applied to various systems for high-throughput
screening.
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GLOSSARY
L
small-molecule ligand
[L]T
total ligand concentration
[L]F
free ligand concentration
P
protein target
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[P]T
total protein concentration
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[P]F
free protein concentration
[PL]
protein-ligand complex concentration
IB
NMR peak height of bound ligand
IF
NMR peak height of free ligand
KD
dissociation equilibrium constant for a protein-ligand complex
c
NMR-linewidth ratio constant
B

NIH-PA Author Manuscript

NMR signal response dependent on fraction of bound ligand
Bsingle
NMR signal response dependent on fraction of bound ligand at a single [P]T and
[L]T
νF
linewidth of the free ligand
νB
linewidth of the bound protein-ligand complex
νP
linewidth of the protein
νobs
observed linewidth change upon addition of protein or ligand
fB
fraction bound complex in solution
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fF
fraction of free ligand in solution
T2−1
dipole-dipole relaxation constant
τc
correlation time
J(ω)

normalized density function of T2−1

Bo
static magnetic field strength
ωo
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Larmor frequency
MWP
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molecular weight of a protein target
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APPENDIX
The binding of a protein (P) with a single small ligand (L) can be represented by the following
reaction.
(A1)

The dissociation equilibrium constant for this system is described by the expression in eq A2,
where the concentrations [P]F, [L]F and [PL] represent the concentration of free protein, free
ligand, and protein-ligand complex, respectively.

(A2)
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Based on mass balance, eq A3 can be used to express [L]F and [PL] in terms of the total ligand
concentration and other concentrations in this system.
(A3)

Substitution of these relationships into eq A2 gives eq A4.

(A4)
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Eq A4 can now be rearranged into the following form,
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(A5)

which makes it possible to solve for [P]F by using the quadratic formula, as indicated in eq A6,
where only the positive root has any meaning in a real protein-ligand system.

(A6)

The bound fraction of ligand fB is next defined as given in eq A7.
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(A7)

If we substitute the positive root of eq A6 into eq A7, the result is eq A8.

(A8)

A further simplification of eq 8 can be accomplished by expanding the square root as a power
4K [P] series where
about x = 0. This approach is valid as long as the
ligand is in considerable excess relative to the protein. The power series that is used here is
shown below.

NIH-PA Author Manuscript

(A9)

If eq A9 is truncated at the second term, this allows the square root term in eq A8 to be written
in the approximate form that is given in eq A10.

(A10)
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The overall result of this simplification is that eq A8 converts to the expression shown below,
there the fraction of bound ligand fB is now described in terms of only KD, the total ligand
concentration and the total protein concentration.

(A11)

If it is assumed that the observed free and bound NMR-linewidths are represented by νF and
νB, respectively, and that exchange occurs between free and bound states, the general solution
to the NMR lineshape is bilorentzian. In the slow limit, the spectrum is obviously just a sum
of the spectra of free and bound species, weighted by their relative abundances. If exchange
rates become comparable to the inverse linewidths, then a conventional solution of the pair of
coupled linear differential equations, including auto and cross relaxation terms but neglecting
any chemical shift difference between the states, gives a time domain (free induction decay):
(A12.a)

NIH-PA Author Manuscript

with

(A12.b)

(A12.c)

(A12.d)

(A12.e)
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(A12.f)

(A12.g)
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(A12.h)

(A12.i)

(A12.j)

where ML and MPL are the magnetization of the free and bound species, respectively. In the
fast exchange limit, the solution is still formally biexponential, but the coefficient c– goes to
zero, and the free induction decay signal, normalized to unity at zero time, becomes

(A13)

NIH-PA Author Manuscript

Fourier transforming, the fast exchange NMR signal height can be written as shown in eq A14:

(A14)

where IF is the height of the ligand signal in the absence of protein and IB is the observed peak
height of the bound complex. This is exactly the same as the height of the free ligand signal in
extreme slow exchange! Rearranging eq A14 explains the observed decrease in NMR peak
signal for a free small-molecule ligand upon its binding to a protein. The relative ratio of NMR
peak height ( ) is now in terms of the fraction of free ligand (fF) and the fraction of bound
ligand (fB) and is dependent on the observed increase in NMR-linewidth upon the binding of
a ligand to a protein.
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(A15)

Inserting A11 into A15 provides a measure of the dissociation equilibrium constant for the
protein-ligand complex by relating the fraction of bound ligand to the observed change in NMR
peak height.

(A16)
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The NMR-linewidth ratio, c, is then measured by using the free ligand NMR spectrum and by
assuming that the linewidth of the bound complex approximates the linewidth of the protein.
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Figure 1.

1D 1H NMR spectra for titration of 20 μM of the drugs phenytoin (A) and naproxen (B) with
increasing concentrations of HSA. The concentrations of HSA were as follows: (i) 0 μM, (ii)
0.4 μM, (iii) 1 μM, (iv) 2 μM, and (v) 4 μM. As the protein concentration increases, the height
of the ligand NMR signal decreases due to the bound ligand adopting the shorter relaxation
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) is proportional
time of the protein. The I decrease in the ratio of NMR signal height (
to the degree of binding such that tighter binding ligands will relax more quickly than weaker
binding ligands. This relationship provides an estimate of the dissociation constant for a
protein-ligand complex.
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Figure 2.

Experimental fractional occupancy (B) for naproxen (●), tolbutamide (▲), and phenol red
(◆) versus the total concentration of HSA. The best-fit lines were obtained using eq 8. The
r2 for these best-fit lines are given in the text and the KD values that were obtained from these
lines are provided in Table 1.
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Figure 3.
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(A) Comparison of 27 experimental protein correlation times determined using NMR dynamics
data with correlation times predicted from protein MW using eq 12 and a shape constant of
1.32. A best-fit line is shown with a slope of 1 and an R2 of 0.81. (B) A plot of linewidth versus
protein molecular weight based on eq 12 for spherical proteins with ρ of 1 (solid line) and
elliptical proteins with ρ of 1.32 (dashed).
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Figure 4.
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Use of NMR in a single-point binding analysis for several small-molecule ligands with known
interactions with the protein HSA. The curves in (A) and (B) represents the ideal single-point
KD values calculated from eq 7 with 0.2 μM HSA and an average c value of 45.7 ± 11.6. (A)
The KD values and errors reported in Table 1 are superimposed on the ideal fit. The KD values
are based on the best-fit to eq 8 using the c values determined for each individual compound.
(B) The KD for each compound was re-calculated based on the best-fit to eq 8 using the c values
from Table 1. The error bars in B represent the range of KD values measured from the range
of c values with the error in the free ligand linewidth, νF, propagated.
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0.365 0.3360 0.3764 0.560 0.5249 1.062 1.2545 1.2655 1.7456
1.8948 2.0845 2.850 4.7656 5.56 50 5.6853 8.3348 7.1744 18.265
23.8135 25.6435
0.8357 1.2562 7.0954 10.661 23.759
1.3262
0.6758 2.0467
5.2651 52.6343
1.6154 2.1752 2.2752 2.9451 3.0352 3.446 3.761 3.8547 4.7652
5.346 6.846
0.6751 1.43 291.946 5.4347 8.446 1146 15.1349
5.2651 15.1552 32.1552 35.7152 14161
0.6363 1.4358
4.536 2551 31.2554
1.337 35.758
5035 58.835 62.535 71.4366 96.1535 11135 153.8535 21135 24435
568.2351342.335

Ibuprofen

Phenylbutazone
Salicylate
Bromocresol Green
Tolbutamide
Phenol Red
Phenytoin

Naproxen
Clofibrate
Bromophenol Blue
Furosimide
Warfarin

Literature KD (μM)

Ligand

3.7 ± 0.6
1.4 ± 0.8
2.7 ± 0.3
2.7 ± 0.4
1.6 ± 0.5
2.0 ± 0.6

1.8 ± 0.6
1.7 ± 0.1
2.5 ± 0.4
1.5 ± 0.8
2.3 ± 0.9

2.3 ± 0.2

Linewidth (Hz)

25.2
63.6
35.1
34.9
58.7
46.8

51.3
54.3
37.8
57.6
41.7

41.5

c

6.5 ± 2.9
7.2 ± 2.9
7.4 ± 2.1
10.2 ± 1.2
36.8 ± 6.5
131.6 ± 12.5

0.7 ± 1.2
1.7 ± 3.4
3.0 ± 2.3
3.4 ± 3.0
4.0 ± 2.8

0.5 ± 1.0

Measured KD (μM)
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